drugset / Trial / NCT02397460
Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)
Phase 2
Completed
50 enrolled
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
RandomizedCrossoverQuadruple-blindTreatment
Summary
The primary objective of this double-blind crossover study is to assess the effect of single doses of 50 mg and 300 mg gefapixant (AF-219/MK-7264) on cough reflex sensitivity to capsaicin in both healthy participants and participants with chronic cough. This study will also assess the effect of single doses of gefapixant on cough reflex sensitivity to adenosine triphosphate (ATP) in healthy participants and participants with chronic cough.
Timeline
- Start
- 2015-04-29
- Primary completion
- 2016-04-22
- Completion
- 2016-05-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefapixant | Small molecule | 50 mg | Oral |
| Subject | Gefapixant | Small molecule | 300 mg | Oral |